Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
1.595
-0.155 (-8.86%)
At close: Nov 20, 2026, 4:00 PM EST
1.630
+0.035 (2.19%)
After-hours: Nov 20, 2026, 7:57 PM EST
Atossa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
16
Market Cap
15.92M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 18.67M |
| Evaxion | 7.49M |
| Lipocine | 3.74M |
| BeyondSpring | 1.88M |
| Cocrystal Pharma | 435.00K |
| CervoMed | 8.73K |
ATOS News
- 10 days ago - Atossa Therapeutics reports Q3 EPS (56c) vs. ($1.01) - TheFly
- 10 days ago - Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update - PRNewsWire
- 10 days ago - Atossa Therapeutics Quarterly report: Q3 2026 - Filings
- 10 days ago - Atossa Therapeutics Earnings release: Q3 2026 - Filings
- 4 weeks ago - Atossa Therapeutics says common stock to begin trading with stapled CVR - TheFly
- 4 weeks ago - Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today - PRNewsWire
- 6 weeks ago - Atossa Therapeutics enters Stapled Contingent Value Rights Agreement - TheFly
- 6 weeks ago - Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value - PRNewsWire